CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 446 enrolled
Drug / intervention
Belatacept +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01820572
NCT01820572Phase 3Completed
CompareCT.gov

Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based Immunosuppression

Bristol-Myers Squibb·interventional·Posted Mar 29, 2013·Updated Jan 5, 2021

In Brief

A Phase 3 clinical trial evaluating Belatacept, Tacrolimus, and 1 other intervention for Kidney Transplantation. Completed, enrolled 446 participants across 117 sites in 10 countries.

Detailed Summary

The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-60 months after kidney transplant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Transplantation
CountriesArgentina, Austria, Colombia, France, Germany, Netherlands, Norway, Sweden, Switzerland, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 29, 2013
Enrollment StartMar 27, 2013
Primary CompletionOct 24, 2019
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 13.3 years ago

Interventions

Belataceptdrug

Tacrolimusdrug

Cyclosporinedrug